(UroToday.com) Despite active surveillance being the preferred management option for low-risk prostate cancer, formal guidelines on optimal follow-up are inconsistent and practices vary considerably across treatment centers. At the American Urological Association (AUA) 2020 virtual annual meeting, Dr. Monique Roobol and colleagues presented results of their study describing the risk of upgrading and conversion to treatment among men on active surveillance, according to the intensity of repeat biopsy during follow-up.